Please read this informative blog post by clinical microbiology and postdoctoral fellow, Thea Brennan-Krohn: "AST FOR NEW ANTIBIOTICS: THE CLINICAL LABORATORIAN'S DILEMMA."
Congratulations to Anthony Kang, PhD, and colleagues on our publication: "In Vitro Apramycin Activity Against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa" published online today in Diagnostic Microbiology and Infectious Disease
The manuscript highlights the remarkable activity of apramycin against multidrug-resistant, extensively drug resistant and pandrug-resistant Acinetobacter and Pseudomonas. Both organisms are significant multidrug-resistance threats. Importantly, frank resistance to apramycin was observed in < 2% of isolates. Apramycin is an aminocyclitol-based aminoglycoside that is currently approved for veterinary use. The activity in these groups of bacteria was especially notable in light of the high level of resistance of the same strain set to aminoglycosides (amikacin, gentamicin, tobramycin) approved for human use. This study complements our prior study, also published in DMID, demonstrating activity of apramycin against a high proportion of carbapenem-resistant Enterobacteriaceae strains.
We are competing in the STAT Madness competition for Innovations in Biomedical Science. Please vote for us!!!!
Here is the link to to the STAT Madness competition: www.statnews.com/feature/stat-madness/bracket/. Please vote for BIDMC in the line up. Our research on discovery of antimicrobials targeting carbapenem-resistant Enterobacteriaceae is highlighted. See "Validation of a High-Throughput Screening Assay for Identification of Adjunctive and Directly Acting Antimicrobials Targeting Carbapenem-Resistant Enterobacteriaceae" published in Assay and Drug Development Technologies and accompanying editorial for more information."
I am looking forward to giving a podium and poster presentation at the ASM Conference on Antibacterial Development. I will be discussing our efforts to accelerated antimicrobial susceptibility testing diagnostics. More rapid and flexible AST diagnostics are critical for clinical introduction and for directing appropriate use of new antimicrobials under development.
is now highlighted on the homepage of ASSAY and Drug Development Technologies with an accompanying press release. Lucius Chiaraviglio's manuscript from 2014 on real-time cytotoxicity detection in high throughput screening assays is also highlighted on the ADT home page too!
Jennifer Tsang presents poster on plasmid-eviction screen at Harvard Medical School Pathology Retreat
Jennifer presented a poster at the Harvard Medical School Annual Pathology Retreat describing proof-of-principle for a high throughput screen for small molecules that evict drug resistance plasmids and restore antimicrobial susceptibility.
Postdoctoral fellow, Jennifer Tsang, publishes a commentary titled "Horizontal Gene Transfer as a Global Mediator of Antimicrobial Resistance" In Post Doc Journal. In the review, she discusses recent evidence for marine environments as a reservoir for antimicrobial resistance genes and a One Health concept of antimicrobial resistance.
Kirby Lab Blog